What's the scoop? Exelixis' flagship cancer medication cabozantinib -- sold under the brand names Cabometyx and Cometriq -- has slowly but surely evolved into a bona fide blockbuster candidate. In 2012, the company grabbed its first indication for cabozantinib as a treatment for medullary thyroid cancer. Four years later, Exelixis was able to tack on a later-line kidney cancer indication to the drug's label, and most recently, the Food and Drug Administration further expanded its label to include patients with advanced liver cancer.